{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:02:26Z","timestamp":1792414946383,"version":"4.4.0"},"reference-count":34,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T00:00:00Z","timestamp":1548288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Forschungsfonds zur F\u00f6rderung exzellenter Nachwuchsforschender","award":["2016\/17"],"award-info":[{"award-number":["2016\/17"]}]},{"name":"Science Pool of the University Hospital Basel, Switzerland"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>The anthelminthic ivermectin is receiving new attention as it is being repurposed for new indications such as mass drug administrations for the treatment of scabies or in malaria vector control. As its pharmacokinetics are still poorly understood, we aimed to characterize the population pharmacokinetics of ivermectin in plasma and dried blood spots (DBS), a sampling method better suited to field trials, with special focus on the influence of body composition and enterohepatic circulation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a clinical trial in 12 healthy volunteers who each received a single oral dose of 12\u00a0mg ivermectin, and collected peripheral venous and capillary DBS samples. We determined ivermectin concentrations in plasma and DBS by liquid chromatography tandem mass spectrometry using a fully automated and scalable extraction system for DBS sample processing. Pharmacokinetic data were analysed using non\u2010linear mixed effects modelling.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A two\u2010compartment model with a transit absorption model, first\u2010order elimination, and weight as an influential covariate on central volume of distribution and clearance best described the data. The model estimates (inter\u2010individual variability) for a 70\u00a0kg subject were: apparent population clearance 7.7 (25%) l\u00a0h<jats:sup>\u22121<\/jats:sup>, and central and peripheral volumes of distribution 89 (10%) l and 234 (20%) l, respectively. Concentrations obtained from DBS samples were strongly linearly correlated (<jats:italic>R<\/jats:italic><jats:sup>2<\/jats:sup>\u00a0=\u00a00.97) with plasma concentrations, and on average 30% lower.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The model accurately depicts population pharmacokinetics of plasma and DBS concentrations over time for oral ivermectin. The proposed analytical workflow is scalable and applicable to the requirements of mass drug administrations.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.13840","type":"journal-article","created":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T19:13:06Z","timestamp":1545246786000},"page":"626-633","source":"Crossref","is-referenced-by-count":43,"title":["Population pharmacokinetics of oral ivermectin in venous plasma and dried blood spots in healthy volunteers"],"prefix":"10.1111","volume":"85","author":[{"given":"Urs","family":"Duthaler","sequence":"first","affiliation":[{"name":"Division of Clinical Pharmacology &amp; Toxicology University Hospital Basel  Switzerland"},{"name":"Department of Biomedicine University of Basel  Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Suenderhauf","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology &amp; Toxicology University Hospital Basel  Switzerland"},{"name":"Department of Biomedicine University of Basel  Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats O.","family":"Karlsson","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Biosciences Uppsala University  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Hussner","sequence":"additional","affiliation":[{"name":"Biopharmacy, Department of Pharmaceutical Sciences University of Basel  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henriette","family":"Meyer zu Schwabedissen","sequence":"additional","affiliation":[{"name":"Biopharmacy, Department of Pharmaceutical Sciences University of Basel  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Kr\u00e4henb\u00fchl","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology &amp; Toxicology University Hospital Basel  Switzerland"},{"name":"Department of Biomedicine University of Basel  Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0658-9330","authenticated-orcid":false,"given":"Felix","family":"Hammann","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology &amp; Toxicology University Hospital Basel  Switzerland"},{"name":"Department of Biomedicine University of Basel  Switzerland"},{"name":"Department of Pharmaceutical Biosciences Uppsala University  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,1,24]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-017-1801-4"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001883"},{"key":"e_1_2_9_4_1","first-page":"CD002219","article-title":"Ivermectin for onchocercal eye disease (river blindness)","volume":"8","author":"Ejere HO","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_5_1","unstructured":"Mectizan Donation Program.Annual highlights 2015. Available athttps:\/\/mectizan.org\/wp\u2010content\/uploads\/2017\/03\/MDP_AnnHigh2015_Design\u2010041516FINAL2\u20101.pdf(last accessed 6 June 2018)."},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500987"},{"key":"e_1_2_9_7_1","unstructured":"PhRMA.Biopharmaceutical Research & Development: The Process Behind New Medicines 2015. Available athttp:\/\/phrma\u2010docs.phrma.org\/sites\/default\/files\/pdf\/rd_brochure.pdf(last accessed 30 June 2018)."},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-007-9000-9"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4612-3626-9_7"},{"key":"e_1_2_9_10_1","first-page":"609","article-title":"Determination of ivermectin in human plasma by high\u2010performance liquid chromatography","volume":"43","author":"Krishna DR","year":"1993","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000236"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-017-1923-8"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trstmh.2005.05.017"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.145.5.1009"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.148.1.6344137"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gcb.2008.02.007"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2350-11-111"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.11.53"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1079\/BJN19740060"},{"key":"e_1_2_9_20_1","first-page":"480","article-title":"Body composition from fluid spaces and density: analysis of methods, 1961","volume":"9","author":"Siri WE","year":"1993","journal-title":"Nutrition"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-2607(98)00067-4"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2003.11.003"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40495-017-0096-z"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1121"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13883"},{"key":"e_1_2_9_26_1","unstructured":"Merck BV. Stromectol\u00aeProduct Information.2009."},{"key":"e_1_2_9_27_1","unstructured":"European Medicines Agency Guideline on bioanalytical method validation 2015. Available athttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2011\/08\/WC500109686.pdf(last accessed 1 February 2018)."},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-007-9066-0"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199630050-00001"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.1367"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky254"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-014-2999-2"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2007.76.1153"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006020"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/009127002237994"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13840","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13840","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.13840","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13840","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T10:29:10Z","timestamp":1694341750000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.13840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,24]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.1111\/bcp.13840"],"URL":"https:\/\/doi.org\/10.1111\/bcp.13840","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,24]]}}}